Yes — and this is one of XT73's primary indications. The bio-cellulose creates a protective, active-delivering seal over the needled skin without risk of irritation. Beta-Glucan and Centella Asiatica are particularly effective at reducing post-needling redness and supporting channel recovery. For standard microneedling (1–2mm) in suitable candidates, Protocol B applies: XT73 immediately, then transition to HPT78 Firming at 24–72h once the barrier has stabilised.

Yes. XT73 is specifically formulated for the disrupted skin barrier state that follows chemical exfoliation — at all depths. For superficial peels (glycolic, lactic), Protocol B applies for suitable candidates: XT73 immediately, HPT78 Firming after 24–48h. For medium-depth peels (TCA 15–25%), Protocol A applies: XT73 immediately and continued at home for 48–72h, with no stimulating actives until barrier is confirmed stable. For deep peels, Protocol A only.

XT73 and HPT78 serve two distinct clinical objectives within the same post-treatment system. XT73 is the first responder: its active complex is built around barrier stabilisation, anti-inflammatory modulation, and creating the optimal conditions for the skin's repair cascade. It is appropriate for every patient and every treatment type. HPT78 is the amplifier: its peptide-driven active complex stimulates fibroblast activity and collagen synthesis to extend and amplify treatment outcomes. It is appropriate for suitable candidates where the primary objective is firming and remodelling, not urgent repair. For most moderate-disruption procedures, the answer is both — sequentially.

Yes. XT73 is formulated without fragrance, alcohol, or known irritants. The active complex is calming by design and safe across all Fitzpatrick types, including skin with a history of post-inflammatory hyperpigmentation, rosacea-prone skin, and highly sensitised or compromised barriers. There are no contraindications.

Yes — and we recommend it as part of the structured take-home protocol. Prescribing XT73 for the 48–72 hours following a procedure extends the clinical benefit of your in-clinic application, improves compliance with post-treatment care, and generates retail revenue. A box of 5 is an ideal starter prescription post-procedure.

Standard cotton or hydrogel sheet masks sit on top of the skin and allow significant evaporation of actives. Bio-cellulose — produced through bacterial fermentation — forms a second-skin seal that holds actives in sustained contact with the skin surface, releasing them slowly and consistently rather than evaporating rapidly. The nanofibrillar structure also drives actives more effectively into the epidermis. In the post-treatment state, where the barrier is disrupted and permeability is elevated, this delivery profile is clinically meaningful.

Yes. While XT73 is optimised for post-procedure recovery, it is equally effective as a clinical intervention for ongoing barrier compromise — over-exfoliated skin, rosacea flares, eczema-prone skin, post-isotretinoin sensitivity, and acne-related inflammation. In these cases it functions as a standalone barrier-repair and calming treatment rather than a post-procedure recovery tool.